Ibuprofen-derived fluorescence inhibitor of COX-2 for breast cancer imaging, prevention and treatment
Source abstract
Abstract
Abstract The integration of precise detection, long-term prevention and effective treatment are beneficial to monitor cancer bioactivity and prevent malignant metastasis for breast cancer patients. Herein, a novel fluorescence probe (IBLN) is designed and synthesized which contains a fluorophore (naphthalimide), a linker and a non-steroidal anti-inflammatory drug (ibuprofen). The specific optical imaging, prevention and treatment effects of breast cancer are relied on the introduction of a powerful cyclooxygenase-2-specific inhibitor, ibuprofen, which makes IBLN possible to successfully differentiate breast cancer cells from normal cells. In addition, fluorescent cellular imaging agent naphthalimide also has anticancer effects via inducing lysosomal membrane permeabilization (LMP). The multi-functional ibuprofen-derived fluorescence inhibitor IBLN realizes the imaging, prevention and treatment for breast cancer, which the selectivity and anticancer effects would be strengthened compared to the single naphthalimide or ibuprofen. Therefore, we envisage that the multi-function strategy in IBLN would be attractive way to explore potential reagent for fluorescence-visible breast cancer therapy in situ.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Inflammatory mediators and NSAID effects · Nanoplatforms for cancer theranostics · Cancer, Stress, Anesthesia, and Immune Response
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. An electrochemical nanobiosensor for plasma MiRNA-155, based on graphene oxide and gold nanorod, for early detection of breast cancer10.1016/j.bios.2015.09.020 ↗
2. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's health initiative
3. Mg(1-x)CuxFe2O4 superparamagnetic nanoparticles as nano-radiosensitizer agents in radiotherapy of MCF-7 human breast cancer cells10.1088/1361-6528/ab8cf2 ↗
4. Cancer treatment and survivorship statistics, 2016
5. Subtype-dependent relationship between young age at diagnosis and breast cancer survival10.1200/JCO.2015.65.8013 ↗
6. Targeting the IRE1-XBP1 Axis to overcome endocrine resistance in breast cancer: opportunities and challenges10.1016/j.canlet.2020.05.020 ↗
7. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials10.1016/S0140-6736(11)60993-8 ↗
8. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials10.1016/S0140-6736(14)60488-8 ↗
9. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials10.1200/JCO.2016.72.0722 ↗
10. Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: a population-based cohort study10.1002/ijc.31411 ↗
11. Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated Cathepsin B inhibitor10.1002/anie.201402305 ↗
12. Recent progress in the green synthesis of rare-earth doped upconversion nanophosphors for optical bioimaging from cells to animals10.1016/j.cjche.2018.03.005 ↗
13. Near-infrared chemiluminescent probe for real-time monitoring singlet oxygen in cells and mice model10.1021/acssensors.0c01291 ↗
14. Highly selective red-emitting fluorescent probe for imaging cancer cells in situ by targeting pim-1 kinase10.1021/acsami.7b14553 ↗
15. Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy10.1039/C6CS00908E ↗
16. Fluorescence sensing of circulating diagnostic biomarkers using molecular probes and nanoparticles10.1021/acssensors.6b00625 ↗
17. Imaging and inhibiting: a dual function molecular flare for cancer cells10.1021/acs.analchem.9b02558 ↗
18. An off-on COX-2-specific fluorescent probe: targeting the golgi apparatus of cancer cells10.1021/ja4056905 ↗
19. Antiinflammatory and analgesic effect of herbal cocktail hongbaekjeong via inhibition of proinflammatory cytokines and prostaglandin E2 release10.1007/s11434-014-0360-0 ↗
20. The role of COX-2 inhibition in breast cancer treatment and prevention10.1053/j.seminoncol.2004.03.042 ↗
21. In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by zika virus10.1038/s41598-017-17765-5 ↗
22. Cyclooxygenase-2 (COX-2)-Dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells10.1016/j.bcp.2003.12.014 ↗
23. Han JA cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells10.1038/emm.2007.51 ↗
24. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines10.1046/j.1442-2042.2001.00332.x ↗
25. Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress10.5115/acb.2017.50.4.293 ↗
26. COX-2 as a target for cancer chemotherapy10.1016/S1734-1140(10)70262-0 ↗
27. Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker10.1016/j.bmcl.2012.10.131 ↗
28. Luminescent iridium(iii) complexes as COX-2-specific imaging agents in cancer cells10.1039/C6CC08109F ↗
29. NSAIDs and cancer prevention: targets downstream of COX-210.1146/annurev.med.57.121304.131253 ↗
30. Breast cancer and nonsteroidal anti-inflammatory drugs
31. Diruthenium(ii,iii) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer–lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells10.1039/C7NR01582H ↗
32. Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein10.1158/0008-5472.CAN-03-3814 ↗
33. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review)10.1016/S0022-5347(01)68393-9 ↗
34. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis10.1002/ijc.1376 ↗
35. Recent advances in the development of 1,8-naphthalimide based DNA targeting binders, anticancer and fluorescent cellular imaging agents10.1039/c2cs35467e ↗
36. Intercalative binding to DNA of antitumour drugs derived from 3-nitro-1,8-naphthalic acid10.1093/nar/7.1.217 ↗
37. Design, synthesis and evaluation of naphthylamide derivatives as potential anticancer agents for hepatocellular carcinoma10.3390/molecules22020342 ↗
38. A new class of naphthylamide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis10.1021/jm100025u ↗
39. Lysosomal membrane permeabilization in cell death10.1038/onc.2008.310 ↗
40. Photooxidative damage to lysosomes of cultured macrophages by acridine orange10.1111/j.1751-1097.1990.tb01685.x ↗
41. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion10.1084/jem.20021952 ↗
42. Modulation of the cyclin-dependent kinase inhibitor p21 (WAF1/Cip1) gene by Zacl through the antagonistic regulators p53 and histone decetylase 1 in Hela Cells10.1158/1541-7786.MCR-08-0123 ↗
43. Effects of genistein on cell proliferation and cell cycle arrest in nonneoplastic human mammary epithelial cells: involvement of Cdc2, p21 (waf/cipl), p27 (kipl), and Cdc25C expression10.1016/S0006-2952(01)00572-X ↗
44. Pharmacological analysis of cyclooxygenase-1 in inflammation10.1073/pnas.95.22.13313 ↗
45. Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin10.1111/apt.13776 ↗
46. Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC10.1152/ajpcell.00196.2016 ↗